Key result
IV nitroglycerin shows no clinical or myocardial preservation benefit over placebo in acute MI.
Why the study?
The potential of intravenous nitroglycerin administered early after acute myocardial infarction to improve clinical outcomes and preserve ischemic myocardium was uncertain.
Does intravenous nitroglycerin improve clinical outcomes or preserve ischemic myocardium in patients with acute myocardial infarction?
RCT (n=104)
Does intravenous nitroglycerin improve clinical outcomes or preserve ischemic myocardium in patients with acute myocardial infarction?
Intravenous nitroglycerin did not significantly improve overall outcomes in acute myocardial infarction, but retrospective analysis suggests potential benefit in reducing infarct complications if administered within 10 hours of symptom onset.
No takes yet. Share an insight, caveat, or question.
No overall benefit from post-MI IV nitroglycerin; leaves open possible subgroup effects for prospective trials.
Flaherty et al. (1983) conducted an RCT in Acute myocardial infarction (n=104). Intravenous nitroglycerin vs. Placebo was evaluated on Clinical improvement and/or evidence of preservation of ischemic myocardium. Intravenous nitroglycerin administered for 48 hours after acute myocardial infarction did not significantly improve overall clinical or laboratory outcomes compared to placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: